M65® ELISA (PEVIVA®)

$210.00

Apoptosis + Necrosis.
Human intermediate filament protein cytokeratin 18 (K18).
Released from human epithelial cells.

Brand

SKU: 10020 Category:

Description

  • Intended Use:
    Quantitative measurement of total soluble cytokeratin 18 (K18) released from dead cells (necrotic and apoptotic). The cells or tissues should be of human epithelial origin (e.g. kidney, gut, colon, lung or liver) expressing K18.
    The M65® ELISA can be combined with the M30-Apoptosense® ELISA (PEVIVA Prod. No. 10010) for determination of cell death mode (apoptosis versus necrosis). Death mode can be determined in vitro and in serum from cancer patients (Kramer et al., Cancer Res. 2004).

Specifications

Cat-Nr.: 10020
Range: 125 - 2000 U/L (The Units measured by the M65® ELISA are defined against a synthetic standard. 1 U/L = 1.24 pM.)
Sensitivity: 25 U/L
Incubation time: 2 hours 20 minutes
Sample volume: 25 µl
Sample type:

serum, plasma (EDTA, Heparin, Citrate) and cell (epithelial cell

Sample preparation:

Store samples at 2 – 8 °C up to 4 hours. For longer
periods, store samples frozen at -20 °or lower.
Samples can be freeze-thawed without loss of activity it is recommended that repeated freeze thawing should be avoided.

Reference values:

Median level 264 U/L with a range between 136 – 480 U/L.
95th percentile was 413 U/L.
Total soluble K18 (uncleaved and cleaved Keratin 18 representing total cell death (necrosis and apoptosis) was measured in 200 apparently normal Swedish blood donors. Male and female values showed a similar distribution and no age dependency. Based on the distribution the cut-off value for elevated K18 has been set at > 450 U/L.

Species:

Human , primates, bovine

Specificity:

The assay uses two monoclonal antibodies directed to epitopes in the 284 – 396 region of the K18 protein. Soluble full length K18 as well as K18 fragments and protein complexes that expose these epitopes will be detected by the assay.

Tests: 96
Method: ELISA

Safety and Handling

Retrieval:

The Standard provided with the kit contains recombinant material which is not comparable to the fragment measured in the sample and is not adequate for spiking recovery tests. The recovery for the recombinant K18 protein fragment observed in human serum/plasma will be higher than expected.

Digestion:

Recovery for human sera when diluted 1:2 in M65 Standard A (0 Units/L): 126 % (average) and 116 – 139 % (range).
Recovery for human sera when diluted 1:1 to 1:10 in the M65 Sample Dilution Buffer: 106 % (average and 100 – 117 % (range).

Hook:

No high dose “hook effect” occurs before 70 000 U/L.

What Makes Us Unique?

GSA MEDICAL portfolio offers a comprehensive workflow for your lab needs with wide range of tools.

As of 2020, GSA MEDICAL INC. started providing premier Manufacturing services to the diagnostic industry. GSA MEDICAL can effectively analyze the feasibility of reagents for use in rapid immunoassays. This process offers a quick glance as to the potential a reagent or concept may have and can result in saving considerable time and money for GSAMEDICAL’s clients.

We provide strong personal support, technical competence, and experience to ensure customer expectations will be met or exceeded.

Shop Products